European Commission Grants Orphan Medicinal Product Designation for Emmaus Medical’s Sickle Cell TreatmentJuly 17, 2012
Emmaus Medical, Inc., a specialty pharmaceutical and regenerative medicine technology company, and subsidiary of Emmaus Life Sciences, Inc., today announced that the European Commission (EC) has granted Orphan Medicinal Product designation for the company’s investigational drug Levoglutamide (L-glutamine) for the treatment of sickle cell disease.
Read More